Story

Omeros Stock Surges on Surprise Q2 Profit, YARTEMLEA Sales Double Estimates

ENTHMSVIIDZHZH-TWJAKOHI
Aug 13, 20261 min read
Omeros Stock Surges on Surprise Q2 Profit, YARTEMLEA Sales Double Estimates
Text size
Background

Shares of Omeros Corp. (OMER) surged more than 17% in pre-market trading after the company reported second-quarter financial results that significantly beat Wall Street expectations, posting a surprise profit fueled by rapidly accelerating sales of its flagship drug, YARTEMLEA.

Blockbuster Quarter Shatters Expectations

Omeros announced total revenue of $28.5 million for the second quarter, more than double the consensus analyst forecast of $12.67 million, according to its earnings release. The company also reached a major financial milestone by reporting its first-ever GAAP net income, which stood at $13.2 million, or $0.18 per share.

On an adjusted basis, Omeros reported earnings per share of $0.02. This marked a dramatic reversal from the anticipated net loss of $0.25 per share that analysts had projected, signaling a significant shift in the company's financial health.

YARTEMLEA Sales Drive Growth

Sample IUX Markets – In-articleAd

The strong performance was almost entirely driven by YARTEMLEA, an FDA-approved lectin pathway complement inhibitor used to treat a rare complication associated with hematopoietic stem cell transplants. The drug's net revenue reached $28.5 million, a 188% sequential increase from the first quarter.

This rapid commercial uptake allowed Omeros to achieve positive operating cash flow for the first time, a key indicator of financial sustainability for investors. The company's outlook is further supported by a permanent CMS J-code for YARTEMLEA, which facilitates reimbursement, and an active reduction of its convertible debt load.

Market Reaction

Investors responded enthusiastically to the unexpectedly strong quarter. The stock jumped 17.1% in pre-open trading, as reported by Investing.com, bringing its price near its 52-week high of $17.65. The move highlights a significant shift in investor sentiment, which had previously seen the stock trade as low as $3.94 over the past year.

Read next

More on Stocks
Back to latest news

LATEST